MOG antibody disease manifesting as progressive cognitive deterioration and behavioral changes with primary central nervous system vasculitis.

Autoantibodies / immunology Cognitive Dysfunction / diagnosis Demyelinating Autoimmune Diseases, CNS / complications Humans Male Middle Aged Myelin-Oligodendrocyte Glycoprotein / immunology Vasculitis, Central Nervous System / diagnosis
Biopsy MRI Myelin oligodendrocyte glycoprotein (MOG) PCNSV Vasculitis

Journal

Multiple sclerosis and related disorders
ISSN: 2211-0356
Titre abrégé: Mult Scler Relat Disord
Pays: Netherlands
ID NLM: 101580247

Informations de publication

Date de publication:
May 2019
Historique:
received: 14 09 2018
revised: 18 01 2019
accepted: 29 01 2019
pubmed: 10 2 2019
medline: 27 8 2019
entrez: 10 2 2019
Statut: ppublish

Résumé

We report a 60-year-old male with anti-myelin oligodendrocyte glycoprotein (MOG) antibody who developed progressive cognitive deterioration and behavioral changes, with no other focal signs, over 9 months. MRI showed numerous T2-hyperintense lesions with partial contrast enhancement in white and grey matter of cerebrum, cerebellum and spinal cord. A brain biopsy revealed perivascular inflammatory cell infiltration, disturbed vascular continuity and no demyelination, indicative of a lymphocytic pattern of primary CNS vasculitis (PCNSV). Contrast enhancement disappeared after immunotherapy; however, cognitive impairment was not improved. Neurologists should note that MOG antibody disease can present as immunotherapy-resistant progressive cognitive impairment with PCNSV-like histopathology.

Identifiants

DOI: 10.1016/j.msard.2019.01.053 PMID: 30738279
pubmed: 30738279
pii: S2211-0348(19)30050-1
doi: 10.1016/j.msard.2019.01.053
pii:
doi:

Substances chimiques

Autoantibodies 0
MOG protein, human 0
Myelin-Oligodendrocyte Glycoprotein 0

Types de publication

Case Reports Journal Article

Langues

eng

Pagination

48-50

Informations de copyright

Copyright © 2019 Elsevier B.V. All rights reserved.

Auteurs

Toshikazu Baba (T)

Department of Neurology, Neurological Institute, Graduate School of Medical Sciences, Kyushu University, 3-1-1, Maidashi, Higashi-ku, Fukuoka 812-8582, Japan.

Koji Shinoda (K)

Department of Neurology, Neurological Institute, Graduate School of Medical Sciences, Kyushu University, 3-1-1, Maidashi, Higashi-ku, Fukuoka 812-8582, Japan.

Mitsuru Watanabe (M)

Department of Neurology, Neurological Institute, Graduate School of Medical Sciences, Kyushu University, 3-1-1, Maidashi, Higashi-ku, Fukuoka 812-8582, Japan.

Shoko Sadashima (S)

Department of Neuropathology, Neurological Institute, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.

Dai Matsuse (D)

Department of Neurology, Neurological Institute, Graduate School of Medical Sciences, Kyushu University, 3-1-1, Maidashi, Higashi-ku, Fukuoka 812-8582, Japan.

Noriko Isobe (N)

Department of Neurology, Neurological Institute, Graduate School of Medical Sciences, Kyushu University, 3-1-1, Maidashi, Higashi-ku, Fukuoka 812-8582, Japan.

Ryo Yamasaki (R)

Department of Neurology, Neurological Institute, Graduate School of Medical Sciences, Kyushu University, 3-1-1, Maidashi, Higashi-ku, Fukuoka 812-8582, Japan.

Kimihiko Kaneko (K)

Department of Neurology, Tohoku University School of Medicine, Sendai, Japan; Department of Neurology, National Hospital Organization Miyagi Hospital, Miyagi, Japan.

Toshiyuki Takahashi (T)

Department of Neurology, Tohoku University School of Medicine, Sendai, Japan; Department of Neurology, National Hospital Organization Yonezawa Hospital, Yonezawa, Japan.

Toru Iwaki (T)

Department of Neuropathology, Neurological Institute, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.

Jun-Ichi Kira (JI)

Department of Neurology, Neurological Institute, Graduate School of Medical Sciences, Kyushu University, 3-1-1, Maidashi, Higashi-ku, Fukuoka 812-8582, Japan. Electronic address: kira@neuro.med.kyushu-u.ac.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Autoanticorps › MOG antibody disease manifesting as...
questionsmedicales.fr › Troubles mentaux › Troubles neurocognitifs › Troubles de la cognition › Dysfonctionnement cognitif › MOG antibody disease manifesting as...
questionsmedicales.fr › Maladies du système immunitaire › Maladies auto-immunes › Maladies auto-immunes du système nerveux › Maladies démyélinisantes auto-immunes du SNC › MOG antibody disease manifesting as...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › MOG antibody disease manifesting as...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Adulte d'âge moyen › MOG antibody disease manifesting as...
questionsmedicales.fr › Facteurs biologiques › Antigènes › Autoantigènes › Glycoprotéine MOG › MOG antibody disease manifesting as...
questionsmedicales.fr › Maladies du système immunitaire › Maladies auto-immunes › Maladies auto-immunes du système nerveux › Vascularite du système nerveux central › MOG antibody disease manifesting as...